GCA
MCID: TMP003
MIFTS: 68

Temporal Arteritis (GCA)

Categories: Bone diseases, Cardiovascular diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Temporal Arteritis

MalaCards integrated aliases for Temporal Arteritis:

Name: Temporal Arteritis 58 12 54 55 60 15 17 74
Polymyalgia Rheumatica 58 12 77 60 38 56 44 45 15 17 74
Giant Cell Arteritis 58 12 77 54 55 60 38 44 45 15 74
Cranial Arteritis 58 54 55 74
Rhizomelic Pseudopolyarthritis 60 74
Horton Disease 77 60
Gca 58 54
Horton's Giant Cell Arteritis 54
Horton's Temporal Arteritis 54
Giant Cell Arteritis; Gca 58
Arteritis Temporalis 54
Arteritis Cranialis 54
Horton's Arteritis 54
Horton's Disease 12

Characteristics:

Orphanet epidemiological data:

60
giant cell arteritis
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Germany),1-5/10000 (United Kingdom),1-5/10000 (Europe); Age of onset: Adult; Age of death: normal life expectancy;

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
temporal arteritis:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Temporal Arteritis

NIH Rare Diseases : 54 Giant cell arteritis (GCA) is a form of vasculitis, a group of disorders that cause inflammation of blood vessels. GCA most commonly affects the arteries of the head (especially the temporal arteries, located on each side of the head), but arteries in other areas of the body can also become inflamed. The inflammation causes the arteries to narrow, resulting in poor blood flow. Signs and symptoms when arteries in the head are involved may include a throbbing headache on one side or the back of the head, tenderness of the scalp, flu-like symptoms, and/or problems with eyesight. Symptoms when other arteries are involved depend on the location of those arteries. The cause of GCA is still being studied, but it is thought to involve the immune system mistakenly attacking the artery walls. Several genetic and environmental factors may increase a person's risk to develop GCA. Complications of GCA may include permanent vision loss or a stroke, so treating the condition is important. Treatment may include corticosteroids and/or other medications that suppress the immune system. GCA may develop with or after another inflammatory disorder known as polymyalgia rheumatica, which occurs in about 40% to 50% of people with GCA. 

MalaCards based summary : Temporal Arteritis, also known as polymyalgia rheumatica, is related to miliary tuberculosis and aortitis, and has symptoms including muscle weakness, angina pectoris and edema. An important gene associated with Temporal Arteritis is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Prednisone and Anti-Inflammatory Agents have been mentioned in the context of this disorder. Affiliated tissues include testes, tongue and skin, and related phenotypes are joint stiffness and fever

MedlinePlus : 44 Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. Other symptoms include Headaches Pain and tenderness over the temples Double vision or visual loss, dizziness Problems with coordination and balance Pain in your jaw and tongue Your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. There is no single test to diagnose giant cell arteritis, but you may have tests that measure inflammation. Treatment is usually with corticosteroids. Early treatment is important; otherwise there is a risk of permanent vision loss or stroke. However, when properly treated, giant cell arteritis rarely comes back. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

NINDS : 55 Vasculitis is inflammation of blood vessels, which includes the veins, arteries, and capillaries. It occurs when the immune system mistakenly attacks a blood vessel. Vasculitis can also be caused by other immune system disease, an allergic reaction to medicines or toxins, and by certain blood cancers that trigger an immune system reaction. The resulting reduced blood flow can permanently damage the brain, spinal cord, peripheral nervous system, and other organs and tissue. Some forms of vasculitis affect a particular organ, whie others may affect many organs at the same time. Symptoms include headaches (especially a headache that doesn’t go away), fever, weight loss, confusion or forgetfulness leading to dementia, swelling of the brain, pain, vision problems, trouble speaking or understanding, muscle weakness and paralysis, and seizures. Some of the better understood vasculitis syndromes are temporal arteritis (also called giant cell arteritis or cranial arteritis--a chronic inflammatory disorder of large blood vessels) and Takayasu’s disease, which affects larger aortas and may cause stoke.

Wikipedia : 77 Giant-cell arteritis (GCA), also called temporal arteritis, is an inflammatory disease of blood vessels.... more...

Description from OMIM: 187360

Related Diseases for Temporal Arteritis

Diseases in the Temporal Arteritis family:

Juvenile Temporal Arteritis

Diseases related to Temporal Arteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 559)
# Related Disease Score Top Affiliating Genes
1 miliary tuberculosis 30.7 IFNG TNF
2 aortitis 30.5 CRP SMUG1
3 cold agglutinin disease 30.5 CRP IL6
4 vasculitis 30.4 APOH CCL2 CRP TNF
5 polyarteritis nodosa 30.3 APOH CRP IL6
6 posterior scleritis 30.3 TNF TNFRSF10A
7 spondyloarthropathy 30.3 IFNG IL6 TNF
8 anterior uveitis 30.2 CCL2 IL6
9 relapsing polychondritis 30.2 CRP IFNG IL6
10 anca-associated vasculitis 30.2 HLA-DRB1 IL6
11 scleritis 30.1 IFNG TNF
12 uveitis 30.1 CCL2 IFNG TNF
13 arteriovenous fistula 30.1 APOH IL6
14 proliferative glomerulonephritis 30.1 CCL2 IFNG IL6
15 microscopic polyangiitis 30.0 HLA-DRB1 TNF
16 alopecia areata 29.9 IFNG IL1RN PTPN22 TNF
17 ischemic heart disease 29.9 CRP IL6 TNF
18 arteriosclerosis 29.9 CCL2 CRP IL6
19 chlamydia 29.8 CRP IFNG IL6 TNF
20 endocarditis 29.8 APOH CRP IL6 TNF
21 cerebrovascular disease 29.8 CRP IL6 TNF
22 peripheral artery disease 29.8 CCL2 CRP IL6
23 bronchiolitis obliterans 29.7 IFNG IL6 TNF
24 atherosclerosis susceptibility 29.7 CCL2 CRP IL6 TNF
25 intermittent claudication 29.7 APOH CRP IL6
26 meningitis 29.7 CCL2 CRP IFNG IL6 TNF
27 inflammatory bowel disease 29.7 CRP IFNG IL6 TNF
28 retinal vein occlusion 29.6 APOH CCL2 IL6
29 psoriatic arthritis 29.6 CRP HLA-DRB1 IL6 PTPN22 TNF
30 lyme disease 29.6 CRP IL6 TNF
31 colitis 29.6 IFNG IL6 TNF
32 vascular disease 29.6 APOH CCL2 CRP IL6 TNF
33 spondylitis 29.5 CRP IL1RN IL6 TNF
34 synovitis 29.5 CRP IL1RN IL6 TNF
35 q fever 29.5 IFNG IL6 TNF
36 arteries, anomalies of 29.5 CCL2 CRP IL6 TNF
37 chagas disease 29.5 CCL2 IFNG IL6 TNF
38 rheumatic disease 29.4 APOH CRP HLA-DRB1 IFNG TNF
39 peritonitis 29.4 CCL2 CRP IL6 TNF
40 infective endocarditis 29.4 APOH CRP IL6 TNF
41 autoimmune disease 29.4 APOH HLA-DRB1 IFNG IL6 PTPN22 TNF
42 purpura 29.4 APOH CRP IL6 TNF
43 takayasu arteritis 29.3 CRP HLA-DRB1 IL6 TNF
44 ulcerative colitis 29.3 CRP IFNG IL6 TNF
45 myeloma, multiple 29.3 CRP IL6 SMUG1 TNF
46 osteoporosis 29.3 IFNG IL1RN IL6 TNF
47 neuritis 29.2 CCL2 CCL5 IFNG TNF
48 arthritis 29.2 CCL2 HLA-DRB1 IFNG IL1RN IL6 PTPN22
49 pericarditis 29.0 CRP IFNG IL1RN IL6 TNF
50 pneumonia 29.0 CCL2 CCL5 CRP IL6 TNF

Comorbidity relations with Temporal Arteritis via Phenotypic Disease Network (PDN): (show all 24)


Active Peptic Ulcer Disease Acute Cystitis
Aortic Valve Disease 1 Bronchitis
Cerebral Arteritis Chronic Myocardial Ischemia
Conn's Syndrome Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Ischemic Heart Disease
Mitral Valve Disease Nonarteritic Anterior Ischemic Optic Neuropathy
Optic Neuritis Osteoporosis
Polymyositis Premature Ovarian Failure 7
Rheumatoid Arthritis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Temporal Arteritis:



Diseases related to Temporal Arteritis

Symptoms & Phenotypes for Temporal Arteritis

Human phenotypes related to Temporal Arteritis:

60 33 (show top 50) (show all 60)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 joint stiffness 60 33 hallmark (90%) Very frequent (99-80%) HP:0001387
2 fever 60 33 hallmark (90%) Very frequent (99-80%) HP:0001945
3 fatigue 60 33 hallmark (90%) Very frequent (99-80%) HP:0012378
4 weight loss 60 33 hallmark (90%) Very frequent (99-80%) HP:0001824
5 anorexia 60 33 hallmark (90%) Very frequent (99-80%) HP:0002039
6 cerebral ischemia 60 33 hallmark (90%) Very frequent (99-80%) HP:0002637
7 vasculitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0002633
8 headache 60 33 hallmark (90%) Very frequent (99-80%) HP:0002315
9 impaired mastication 33 hallmark (90%) HP:0005216
10 depressivity 60 33 frequent (33%) Frequent (79-30%) HP:0000716
11 arthritis 60 33 frequent (33%) Frequent (79-30%) HP:0001369
12 alopecia 60 33 frequent (33%) Frequent (79-30%) HP:0001596
13 ophthalmoparesis 60 33 frequent (33%) Frequent (79-30%) HP:0000597
14 elevated erythrocyte sedimentation rate 60 33 frequent (33%) Frequent (79-30%) HP:0003565
15 ptosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000508
16 nystagmus 60 33 occasional (7.5%) Occasional (29-5%) HP:0000639
17 diplopia 60 33 occasional (7.5%) Occasional (29-5%) HP:0000651
18 hyperhidrosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000975
19 ataxia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001251
20 muscle weakness 60 33 occasional (7.5%) Occasional (29-5%) HP:0001324
21 sudden cardiac death 60 33 occasional (7.5%) Occasional (29-5%) HP:0001645
22 optic atrophy 60 33 occasional (7.5%) Occasional (29-5%) HP:0000648
23 renal insufficiency 60 33 occasional (7.5%) Occasional (29-5%) HP:0000083
24 arthralgia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002829
25 abdominal pain 60 33 occasional (7.5%) Occasional (29-5%) HP:0002027
26 abnormality of the pleura 60 33 occasional (7.5%) Occasional (29-5%) HP:0002103
27 aortic dissection 60 33 occasional (7.5%) Occasional (29-5%) HP:0002647
28 skin ulcer 60 33 occasional (7.5%) Occasional (29-5%) HP:0200042
29 visual field defect 60 33 occasional (7.5%) Occasional (29-5%) HP:0001123
30 myalgia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003326
31 paresthesia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003401
32 amaurosis fugax 60 33 occasional (7.5%) Occasional (29-5%) HP:0100576
33 hematuria 60 33 occasional (7.5%) Occasional (29-5%) HP:0000790
34 diabetes insipidus 60 33 occasional (7.5%) Occasional (29-5%) HP:0000873
35 vertigo 60 33 occasional (7.5%) Occasional (29-5%) HP:0002321
36 visual loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0000572
37 conductive hearing impairment 60 33 occasional (7.5%) Occasional (29-5%) HP:0000405
38 epistaxis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000421
39 pericarditis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001701
40 recurrent pharyngitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0100776
41 meningitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001287
42 cough 60 33 occasional (7.5%) Occasional (29-5%) HP:0012735
43 hepatic failure 60 33 occasional (7.5%) Occasional (29-5%) HP:0001399
44 arterial thrombosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0004420
45 mediastinal lymphadenopathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0100721
46 gastrointestinal infarctions 60 33 occasional (7.5%) Occasional (29-5%) HP:0005244
47 gangrene 60 33 occasional (7.5%) Occasional (29-5%) HP:0100758
48 glossitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000206
49 double outlet right ventricle with subpulmonary ventricular septal defect without pulmonary stenosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0011658
50 abdominal aortic aneurysm 33 occasional (7.5%) HP:0005112

Symptoms via clinical synopsis from OMIM:

58
Eyes:
blindness
retinal arteritis

Lab:
elevated sedimentation rate

Vascular:
temporal arteritis
giant cell arteritis
polymyalgia rheumatica (pmr)

Misc:
response to adrenal glucocorticoids

Clinical features from OMIM:

187360

UMLS symptoms related to Temporal Arteritis:


muscle weakness, angina pectoris, edema, pruritus, back pain, myalgia, chest pain, sciatica, exanthema, muscle cramp, muscle rigidity, muscle spasticity

MGI Mouse Phenotypes related to Temporal Arteritis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.28 CCL2 CCL5 CRP IFNG IL1RN IL6

Drugs & Therapeutics for Temporal Arteritis

Drugs for Temporal Arteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
2 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Omega 3 Fatty Acid Phase 4,Not Applicable
9
Infliximab Approved Phase 3,Phase 2 170277-31-3
10
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 302-25-0
11
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 50-24-8 5755
12
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 83-43-2 6741
13
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 2921-57-5
14
Hydroxychloroquine Approved Phase 3 118-42-3 3652
15
Adalimumab Approved Phase 3 331731-18-1 16219006
16
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
17
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
18
Alendronate Approved Phase 3 66376-36-1, 121268-17-5 2088
19
Etanercept Approved, Investigational Phase 3 185243-69-0
20
Abatacept Approved Phase 3,Phase 2 332348-12-6 10237
21
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
22
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 1406-16-2
25
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
26
Prednisolone hemisuccinate Experimental Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 2920-86-7
27 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Antirheumatic Agents Phase 3,Phase 2,Not Applicable
29 Gastrointestinal Agents Phase 3,Phase 2,Not Applicable
30 Anti-Infective Agents Phase 3,Not Applicable
31 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
32 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Protective Agents Phase 2, Phase 3,Phase 3,Not Applicable
34 Neuroprotective Agents Phase 2, Phase 3,Phase 3,Not Applicable
35 Methylprednisolone Acetate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
36 Antiemetics Phase 2, Phase 3,Phase 3,Not Applicable
37 Prednisolone acetate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
38 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 3,Not Applicable
39 Autonomic Agents Phase 2, Phase 3,Phase 3,Not Applicable
40 Pharmaceutical Solutions Phase 3,Not Applicable
41 Antiprotozoal Agents Phase 3
42 Antiparasitic Agents Phase 3
43 Antimalarials Phase 3
44 Folic Acid Antagonists Phase 3,Phase 2
45 Folate Phase 3,Phase 2
46 Vitamin B9 Phase 3,Phase 2
47 Antimetabolites, Antineoplastic Phase 3,Phase 2
48 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
49 Antimetabolites Phase 3,Phase 2
50 Vitamin B Complex Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
2 Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients Completed NCT01169597 Phase 4 prednisone
3 Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission. Recruiting NCT03244709 Phase 4 Tocilizumab
4 Tocilizumab Plus a Short Prednisone Taper for GCA Recruiting NCT03726749 Phase 4 Tocilizumab;Prednisone
5 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
6 Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica Unknown status NCT01423591 Phase 3 infliximab;inactive powder
7 Hydroxychloroquine in Giant Cell Arteritis Completed NCT00430807 Phase 3 hydroxychloroquine/placebo
8 HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis Completed NCT00305539 Phase 3 adalimumab;placebo
9 An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) Completed NCT01791153 Phase 3 Tocilizumab;Prednisone;Tocilizumab Placebo;Prednisone Placebo;Corticosteroids;Methotrexate
10 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
11 Timed Release Tablet Prednisone in Polymyalgia Rheumatica Completed NCT00836810 Phase 2, Phase 3 Timed Release Tablet Prednisone;Prednisolone
12 Etanercept Treatment in the Early Course of Polymyalgia Rheumatica Completed NCT00524381 Phase 3 Etanercept (Enbrel);Sodium chloride (placebo)
13 A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis Recruiting NCT03725202 Phase 3 Upadacitinib;Corticosteroid (CS)
14 Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA Recruiting NCT03600805 Phase 3 Sarilumab SAR153191;Sarilumab matching placebo;Prednisone;Prednisone matching placebo
15 Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica Recruiting NCT03600818 Phase 3 Sarilumab SAR153191 (REGN88);Sarilumab-matching placebo;Prednisone;Prednisone-matching placebo;Prednisone
16 A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) Recruiting NCT03263715 Phase 3 Tocilizumab Prefilled Syringe [Actemra];Placebos;Glucocorticoids
17 Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE Recruiting NCT02908217 Phase 3 Tocilizumab;Placebo
18 An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) Active, not recruiting NCT03202368 Phase 3 Tocilizumab
19 Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS Active, not recruiting NCT03632187 Phase 3 Abatacept;Placebos
20 Giant Cell Arteritis and Anakinra Trial Not yet recruiting NCT02902731 Phase 3 PLACEBO;ANAKINRA
21 MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial Not yet recruiting NCT03892785 Phase 3 Prednisone treatment;Tocilizumab treatment;Methotrexate treatment
22 Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO Not yet recruiting NCT03841734 Phase 3 treatment
23 Treatment With Leflunomide in Patients With Polymyalgia Rheumatica Not yet recruiting NCT03576794 Phase 3 Leflunomide 20 mg;Prednisolone
24 Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis Terminated NCT02531633 Phase 2, Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone;Placebo to match prednisone
25 A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR Terminated NCT01821040 Phase 3 Lodotra®;Prednisone IR (immediate release)
26 A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA) Withdrawn NCT03192969 Phase 3 Abatacept;Glucocorticoid Treatment
27 Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica Withdrawn NCT02899026 Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone /Prednisone placebo
28 Tocilizumab for Patients With Giant Cell Arteritis Completed NCT01450137 Phase 2 Tocilizumab + Glucocorticoids (GCs);Placebo + Glucocorticoids (GCs)
29 Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis Completed NCT00556439 Phase 2 Abatacept;Placebo
30 Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. Completed NCT01910038 Phase 2 corticoids+ tocilizumab 8mg/Kg/4 weeks
31 Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis Completed NCT00004686 Phase 2 methotrexate;prednisone
32 Tocilizumab Effect iN pOlymyalgia Rheumatica Completed NCT01713842 Phase 2 TCZ
33 Study of Tocilizumab to Treat Polymyalgia Rheumatica Completed NCT01396317 Phase 2 Tocilizumab
34 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
35 KPL-301 for Subjects With Giant Cell Arteritis Recruiting NCT03827018 Phase 2
36 A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis Recruiting NCT03765788 Phase 2 Prednisolone;Placebo to match Secukinumab, s.c.
37 Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab Recruiting NCT03745586 Phase 1, Phase 2 Tocilizumab;Glucocorticoids
38 Ustekinumab for the Treatment of Giant Cell Arteritis Recruiting NCT02955147 Phase 1, Phase 2 Ustekinumab;Prednisone
39 Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis Recruiting NCT03711448 Phase 2 prednisone treatment;prednisone and ustekinumab treatment
40 Baricitinib in Relapsing Giant Cell Arteritis Recruiting NCT03026504 Phase 2 Baricitinib
41 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
42 Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Active, not recruiting NCT01740297 Phase 1, Phase 2 Talimogene laherparepvec;Ipilimumab
43 Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA) Not yet recruiting NCT03812302 Phase 2
44 A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis Terminated NCT00076726 Phase 2 Infliximab
45 Delayed Release Prednisone in PMR Terminated NCT02702778 Phase 2 Delayed-Release (DR) Prednisone;Immediate Release (IR) Prednisone
46 A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica Terminated NCT01364389 Phase 2 AIN457;ACZ885;Prednisone;Placebo
47 MRI Superficial Temporal Artery Completed NCT00188448 Phase 1
48 Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Not yet recruiting NCT03656627 Phase 1 Nivolumab
49 Diagnostic Study of Temporal Arteritis Unknown status NCT01130857
50 Study of Circulating Microparticles in Giant Cell Arteritis Unknown status NCT02333708

Search NIH Clinical Center for Temporal Arteritis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: giant cell arteritis

Genetic Tests for Temporal Arteritis

Anatomical Context for Temporal Arteritis

MalaCards organs/tissues related to Temporal Arteritis:

42
Testes, Tongue, Skin, Brain, Eye, Bone, Spinal Cord

Publications for Temporal Arteritis

Articles related to Temporal Arteritis:

(show top 50) (show all 2190)
# Title Authors Year
1
Interstitial Lung Disease in patients with Polymyalgia Rheumatica: A case series. ( 30603602 )
2019
2
Juvenile temporal arteritis: A clinicopathological multicentric experience. ( 30844551 )
2019
3
Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. ( 29903537 )
2019
4
Examining management and research priorities in patients with polymyalgia rheumatica: a primary care questionnaire survey. ( 30617599 )
2019
5
Development of polymyalgia rheumatica during hospitalization and diagnosis based on history taking by physical and occupational therapists. ( 30631657 )
2019
6
Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis. ( 30649507 )
2019
7
Towards a Core Outcome Measurement Set for Polymyalgia Rheumatica: Report from the OMERACT 2018 Special Interest Group. ( 30709960 )
2019
8
Immune Checkpoint Inhibitor-Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in a Patient After Treatment With Nivolumab. ( 30801332 )
2019
9
Differences of articular and extra-articular involvement in polymyalgia rheumatica: A comparison by whole-body FDG-PET/CT. ( 30843747 )
2019
10
Localized Myofascial Inflammation by Magnetic Resonance Imaging in Recent-Onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy. ( 30877202 )
2019
11
Identification of an activated neutrophil phenotype in polymyalgia rheumatica during steroid treatment: potential involvement of immune cell cross talk. ( 30898854 )
2019
12
Treatment of polymyalgia rheumatica. ( 30904473 )
2019
13
Central retinal vein occlusion in temporal arteritis: red sign or red herring? ( 29361164 )
2018
14
Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica. ( 29121248 )
2018
15
Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab. ( 29370856 )
2018
16
Intravascular Large B-Cell Lymphoma Mimicking Temporal Arteritis. ( 29854538 )
2018
17
Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable. ( 29346621 )
2018
18
The potential for dual pathology in temporal arteritis. ( 29186538 )
2018
19
Dural arteriovenous fistula mimicking temporal arteritis. ( 30504098 )
2018
20
Swollen joints and peripheral arthritis are signs of malignancy in polymyalgia rheumatica. ( 30334628 )
2018
21
Polymyalgia Rheumatica After Herpes-Zoster. ( 30874245 )
2018
22
Polymyalgia Rheumatica and Autoimmune Inflammatory Syndrome Induced by Adjuvants Following Administration of Influenza Vaccine. ( 29708518 )
2018
23
Image Gallery: Bilateral juvenile temporal arteritis. ( 30318798 )
2018
24
Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study. ( 29088976 )
2018
25
Temporal Arteritis Presenting as an Isolated Bilateral Abducens Nerve Palsy: A Rare Case of a 65-year-old Male. ( 30042918 )
2018
26
Bilateral scalp necrosis associated with temporal arteritis. ( 30260140 )
2018
27
18 F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with polymyalgia rheumatica: Screening for vasculitis. ( 29550251 )
2018
28
FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. ( 29637252 )
2018
29
Concomitant Polymyalgia Rheumatica and Large-Vessel Vasculitis Visualized on 18F-FDG PET/CT. ( 29690555 )
2018
30
Primary Care Vasculitis: Polymyalgia Rheumatica and Giant Cell Arteritis. ( 29759126 )
2018
31
Clinical Improvement According to RAPID3 in Patients With Polymyalgia Rheumatica: A Longitudinal Analysis From Routine Care. ( 29424759 )
2018
32
Preliminary concurrent validity of the Fitbit-Zip and ActiGraph activity monitors for measuring steps in people with polymyalgia rheumatica. ( 29427859 )
2018
33
Polymyalgia Rheumatica with Normal Inflammatory Markers. ( 29476746 )
2018
34
Prescribing for polymyalgia rheumatica. ( 29507455 )
2018
35
Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis. ( 29531778 )
2018
36
Perspectives and unmet needs in polymyalgia rheumatica. Providing the fundamental framework for the development of new treatment regimes in polymyalgia rheumatica. ( 29589397 )
2018
37
Pathogenesis of polymyalgia rheumatica. ( 29589398 )
2018
38
Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica. ( 29589399 )
2018
39
The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome. ( 29589400 )
2018
40
Comorbidity in polymyalgia rheumatica. ( 29589401 )
2018
41
The role of the general practitioner and the out-of-hospital public rheumatologist in the diagnosis and follow-up of patients with polymyalgia rheumatica. ( 29589402 )
2018
42
Imaging in polymyalgia rheumatica. ( 29589403 )
2018
43
Update on treatment of polymyalgia rheumatica. ( 29589404 )
2018
44
Lung involvement in polymyalgia rheumatica. ( 29669034 )
2018
45
Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis: a four-point guidance. ( 29686435 )
2018
46
Polymyalgia rheumatica and diverticular disease: just two distinct age-related disorders or more? Results from a case-control study. ( 29732494 )
2018
47
Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor. ( 29760158 )
2018
48
Incidence of cardiovascular events in polymyalgia rheumatica and giant cell arteritis amongst an Asian population: Propensity score matched cohort study. ( 29879315 )
2018
49
Response to: 'Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor' by Chan and Bass. ( 29925509 )
2018
50
Dissecting the inflammatory response in polymyalgia rheumatica: the relative role of IL-6 and its inhibition. ( 29946742 )
2018

Variations for Temporal Arteritis

Expression for Temporal Arteritis

Search GEO for disease gene expression data for Temporal Arteritis.

Pathways for Temporal Arteritis

Pathways related to Temporal Arteritis according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 CCL2 CCL5 CRP HLA-DRB1 IFNG IL1RN
2
Show member pathways
13.22 CCL2 CCL5 HLA-DRB1 IFNG IL1RN IL6
3
Show member pathways
13.18 CCL2 CCL5 IL6 PTPN22 TNF TNFRSF10A
4
Show member pathways
13.07 CCL2 CCL5 IFNG IL6 TNF
5
Show member pathways
12.85 CCL2 CCL5 IL6 TNF TNFRSF10A
6
Show member pathways
12.49 HLA-DRB1 IFNG IL6 TNF
7
Show member pathways
12.48 CCL2 IFNG IL6 TNF
8 12.4 CCL2 CCL5 IFNG IL1RN PTPN22 TNF
9
Show member pathways
12.39 CCL2 CCL5 HLA-DRB1 IFNG IL6 TNF
10
Show member pathways
12.24 CCL2 IFNG IL6 TNF
11 12.13 HLA-DRB1 IFNG IL6 TNF
12
Show member pathways
12.03 CCL2 CCL5 CRP IFNG IL6 SERPINA3
13 12 CCL2 IFNG TNF
14
Show member pathways
11.97 IFNG IL6 TNF
15
Show member pathways
11.96 CCL2 CCL5 IFNG IL6 TNFRSF10A
16
Show member pathways
11.95 IFNG IL6 TNF
17 11.9 IFNG IL6 TNF
18 11.89 CCL2 IL6 TNF
19 11.89 CCL2 IFNG IL6 TNF
20 11.84 CCL2 CCL5 IL6 TNF
21 11.82 CCL2 IL6 TNF
22 11.8 HLA-DRB1 IL6 TNF
23 11.79 IFNG IL6 TNF
24 11.67 IFNG IL6 TNF
25
Show member pathways
11.59 IFNG IL6 TNF
26 11.56 CCL2 CCL5 IL6 TNF
27 11.48 IFNG IL6 TNF
28 11.44 CCL2 IFNG TNF
29 11.42 CCL2 IFNG IL6 TNF
30 11.39 IFNG IL6 TNF
31 11.39 CCL2 CCL5 HLA-DRB1 IFNG IL6 TNF
32 11.34 CCL2 CCL5 IL1RN IL6 TNF
33 11.28 IFNG IL6 TNF
34 11.21 IFNG IL6 TNF
35 11.12 CCL2 CCL5 IL6 TNF
36 11.09 HLA-DRB1 IFNG IL6 TNF
37 10.96 CCL2 SERPINA3
38 10.95 CCL2 CCL5 IFNG IL1RN IL6 TNF
39 10.93 CRP IL6 TNF
40 10.87 CCL2 TNF

GO Terms for Temporal Arteritis

Cellular components related to Temporal Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 APOH CCL2 CCL5 CRP IFNG IL1RN
2 extracellular space GO:0005615 9.28 APOH CCL2 CCL5 CRP IFNG IL1RN

Biological processes related to Temporal Arteritis according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.96 CRP IFNG IL6 PTPN22 TNF
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 CCL2 CCL5 PTPN22 TNF
3 regulation of signaling receptor activity GO:0010469 9.85 CCL2 CCL5 IFNG IL1RN IL6 TNF
4 response to virus GO:0009615 9.82 CCL5 IFNG TNF
5 defense response to Gram-positive bacterium GO:0050830 9.81 CRP IL6 TNF
6 cellular response to lipopolysaccharide GO:0071222 9.81 CCL2 IL1RN IL6 TNF
7 neutrophil chemotaxis GO:0030593 9.8 CCL2 CCL5 IL1RN
8 cytokine-mediated signaling pathway GO:0019221 9.8 CCL2 CCL5 IL1RN IL6 TNF
9 cellular response to organic cyclic compound GO:0071407 9.79 CCL2 CCL5 TNF
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 CCL5 IFNG IL6
11 regulation of insulin secretion GO:0050796 9.78 CCL5 IFNG TNF
12 response to glucocorticoid GO:0051384 9.77 IL1RN IL6 TNF
13 positive regulation of interleukin-6 production GO:0032755 9.76 IL1RN IL6 TNF
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.75 CCL5 IL6 TNF
15 extrinsic apoptotic signaling pathway GO:0097191 9.71 IFNG TNF TNFRSF10A
16 monocyte chemotaxis GO:0002548 9.7 CCL2 CCL5 IL6
17 immune response GO:0006955 9.7 CCL2 CCL5 HLA-DRB1 IFNG IL1RN IL6
18 positive regulation of osteoclast differentiation GO:0045672 9.66 IFNG TNF
19 positive regulation of chemokine production GO:0032722 9.65 IL6 TNF
20 positive regulation of glial cell proliferation GO:0060252 9.65 IL6 TNF
21 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IFNG TNF
22 protein kinase B signaling GO:0043491 9.65 CCL2 CCL5 TNF
23 macrophage chemotaxis GO:0048246 9.64 CCL2 CCL5
24 acute-phase response GO:0006953 9.63 CRP IL6 SERPINA3
25 humoral immune response GO:0006959 9.62 CCL2 IFNG IL6 TNF
26 positive regulation of neuroinflammatory response GO:0150078 9.59 IL6 TNF
27 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.57 IL1RN IL6
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
29 positive regulation of vitamin D biosynthetic process GO:0060557 9.43 IFNG TNF
30 negative regulation of lipid storage GO:0010888 9.43 CRP IL6 TNF
31 lipopolysaccharide-mediated signaling pathway GO:0031663 9.26 CCL2 CCL5 PTPN22 TNF
32 chronic inflammatory response to antigenic stimulus GO:0002439 9.25 TNF
33 inflammatory response GO:0006954 9.17 CCL2 CCL5 CRP IL1RN IL6 SERPINA3

Molecular functions related to Temporal Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.77 APOH CCL2 CCL5 CDK9 CRP IFNG
2 cytokine activity GO:0005125 9.1 CCL2 CCL5 IFNG IL1RN IL6 TNF

Sources for Temporal Arteritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....